Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

ConclusionPembrolizumab demonstrated modest single-agent activity in relapsed or refractory T-cell lymphoma.

Source: Clinical Lymphoma Myeloma and Leukemia - April 25, 2019 Category: Cancer & Oncology Source Type: research